TrialThe patient2015

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.

Jason Brunetta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.